Malignant hepatic vascular tumors in adults: Characteristics,diagnostic difficulties and current management
|
摘要
Malignant vascular tumors of the liver include rare primary hepatic mesenchymal tumors developed in the background of a normal liver parenchyma. Most of them are detected incidentally by the increased use of performing imaging techniques. Their diagnosis is challenging, involving clinical and imaging criteria, with final confirmation by histology and immunohistochemistry. Surgery represents the mainstay of treatment. Liver transplantation(LT) has improved substantially the prognosis of hepatic epithelioid hemangioendothelioma(HEHE), with 5-year patient survival rates of up to 81%, based on the European Liver Intestine Transplantation AssociationEuropean Liver Transplant Registry study. Unfortunately, the results of surgery and LT are dismal in cases of hepatic angiosarcoma(HAS). Due to the disappointing results of very short survival periods of approximately 6-7 mo after LT, because of tumor recurrence and rapid progression of the disease, HAS is considered an absolute contraindication to LT. Recurrences after surgical resection are high in cases of HEHE and invariably present in cases of HAS. The discovery of reliable prognostic markers and the elaboration of prognostic scores following LT are needed to provide the best therapeutic choice for each patient.Studies on a few patients have demonstrated the stabilization of the disease in a proportion of patients with hepatic vascular tumors using novel targeted antiangiogenic agents, cytokines or immunotherapy. These new approaches,alone or in combination with other therapeutic modalities, such as surgery and classical chemotherapy, need further investigation to assess their role in prolonging patient survival. Personalized therapeutic algorithms according to the histopathological features, behavior, molecular biology and genetics of the tumors should be elaborated in the near future for the management of patients diagnosed with primary malignant vascular tumors of the liver.
Malignant vascular tumors of the liver include rare primary hepatic mesenchymal tumors developed in the background of a normal liver parenchyma. Most of them are detected incidentally by the increased use of performing imaging techniques. Their diagnosis is challenging, involving clinical and imaging criteria, with final confirmation by histology and immunohistochemistry. Surgery represents the mainstay of treatment. Liver transplantation(LT) has improved substantially the prognosis of hepatic epithelioid hemangioendothelioma(HEHE), with 5-year patient survival rates of up to 81%, based on the European Liver Intestine Transplantation AssociationEuropean Liver Transplant Registry study. Unfortunately, the results of surgery and LT are dismal in cases of hepatic angiosarcoma(HAS). Due to the disappointing results of very short survival periods of approximately 6-7 mo after LT, because of tumor recurrence and rapid progression of the disease, HAS is considered an absolute contraindication to LT. Recurrences after surgical resection are high in cases of HEHE and invariably present in cases of HAS. The discovery of reliable prognostic markers and the elaboration of prognostic scores following LT are needed to provide the best therapeutic choice for each patient.Studies on a few patients have demonstrated the stabilization of the disease in a proportion of patients with hepatic vascular tumors using novel targeted antiangiogenic agents, cytokines or immunotherapy. These new approaches,alone or in combination with other therapeutic modalities, such as surgery and classical chemotherapy, need further investigation to assess their role in prolonging patient survival. Personalized therapeutic algorithms according to the histopathological features, behavior, molecular biology and genetics of the tumors should be elaborated in the near future for the management of patients diagnosed with primary malignant vascular tumors of the liver.
Malignant vascular tumors of the liver include rare primary hepatic mesenchymal tumors developed in the background of a normal liver parenchyma. Most of them are detected incidentally by the increased use of performing imaging techniques. Their diagnosis is challenging, involving clinical and imaging criteria, with final confirmation by histology and immunohistochemistry. Surgery represents the mainstay of treatment. Liver transplantation(LT) has improved substantially the prognosis of hepatic epithelioid hemangioendothelioma(HEHE), with 5-year patient survival rates of up to 81%, based on the European Liver Intestine Transplantation AssociationEuropean Liver Transplant Registry study. Unfortunately, the results of surgery and LT are dismal in cases of hepatic angiosarcoma(HAS). Due to the disappointing results of very short survival periods of approximately 6-7 mo after LT, because of tumor recurrence and rapid progression of the disease, HAS is considered an absolute contraindication to LT. Recurrences after surgical resection are high in cases of HEHE and invariably present in cases of HAS. The discovery of reliable prognostic markers and the elaboration of prognostic scores following LT are needed to provide the best therapeutic choice for each patient.Studies on a few patients have demonstrated the stabilization of the disease in a proportion of patients with hepatic vascular tumors using novel targeted antiangiogenic agents, cytokines or immunotherapy. These new approaches,alone or in combination with other therapeutic modalities, such as surgery and classical chemotherapy, need further investigation to assess their role in prolonging patient survival. Personalized therapeutic algorithms according to the histopathological features, behavior, molecular biology and genetics of the tumors should be elaborated in the near future for the management of patients diagnosed with primary malignant vascular tumors of the liver.
引文
1 Lerut J,Iesari S.Vascular tumours of the liver:a particular story.Transl Gastroenterol Hepatol 2018;3:62[PMID:30363746 DOI:10.21037/tgh.2018.09.02]
2 Theodosopoulos T,Dellaportas D,Tsangkas A,Tsangkas N,Psychogiou V,Yiallourou A,Polymeneas G,Kondi-Pafiti A.Clinicopathological features and management of hepatic vascular tumors.A 20-year experience in a Greek University Hospital.J BUON 2013;18:1026-1031[PMID:24344033 DOI:10.4103/0973-1482.126493]
3 Weiss SW,Enzinger FM.Epithelioid hemangioendothelioma:a vascular tumor often mistaken for a carcinoma.Cancer 1982;50:970-981[PMID:7093931 DOI:10.1002/1097-0142(19820901)50:53.0.CO;2-Z]
4 Lau K,Massad M,Pollak C,Rubin C,Yeh J,Wang J,Edelman G,Yeh J,Prasad S,Weinberg G.Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement:insights from an internet registry in the study of a rare cancer.Chest 2011;140:1312-1318[PMID:21546438 DOI:10.1378/chest.11-0039]
5 Ishak KG,Sesterhenn IA,Goodman ZD,Rabin L,Stromeyer FW.Epithelioid hemangioendothelioma of the liver:a clinicopathologic and follow-up study of 32 cases.Hum Pathol 1984;15:839-852[PMID:6088383 DOI:10.1016/S0046-8177(84)80145-8]
6 Hsieh MS,Liang PC,Kao YC,Shun CT.Hepatic epithelioid hemangioendothelioma in Taiwan:a clinicopathologic study of six cases in a single institution over a 15-year period.J Formos Med Assoc2010;109:219-227[PMID:20434030 DOI:10.1016/S0929-6646(10)60045-9]
7 Sardaro A,Bardoscia L,Petruzzelli MF,Portaluri M.Epithelioid hemangioendothelioma:an overview and update on a rare vascular tumor.Oncol Rev 2014;8:259[PMID:25992243 DOI:10.4081/oncol.2014.259]
8 Hu HJ,Jin YW,Jing QY,Shrestha A,Cheng NS,Li FY.Hepatic epithelioid hemangioendothelioma:Dilemma and challenges in the preoperative diagnosis.World J Gastroenterol 2016;22:9247-9250[PMID:27895413 DOI:10.3748/wjg.v22.i41.9247]
9 Treska V,Daum O,Svajdler M,Liska V,Ferda J,Baxa J.Hepatic Epithelioid Hemangioendothelioma-a Rare Tumor and Diagnostic Dilemma.In Vivo 2017;31:763-767[PMID:28652454 DOI:10.21873/invivo.11128]
10 Miettinen M,Rikala MS,Rys J,Lasota J,Wang ZF.Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma:an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors.Am J Surg Pathol 2012;36:629-639[PMID:22314185 DOI:10.1097/PAS.0b013e318243555b]
11 Mistry AM,Gorden DL,Busler JF,Coogan AC,Kelly BS.Diagnostic and therapeutic challenges in hepatic epithelioid hemangioendothelioma.J Gastrointest Cancer 2012;43:521-525[PMID:22544493DOI:10.1007/s12029-012-9389-y]
12 Flucke U,Vogels RJ,de Saint Aubain Somerhausen N,Creytens DH,Riedl RG,van Gorp JM,Milne AN,Huysentruyt CJ,Verdijk MA,van Asseldonk MM,Suurmeijer AJ,Bras J,Palmedo G,Groenen PJ,Mentzel T.Epithelioid Hemangioendothelioma:clinicopathologic,immunhistochemical,and molecular genetic analysis of 39 cases.Diagn Pathol 2014;9:131[PMID:24986479 DOI:10.1186/1746-1596-9-131]
13 Mehrabi A,Kashfi A,Fonouni H,Schemmer P,Schmied BM,Hallscheidt P,Schirmacher P,Weitz J,Friess H,Buchler MW,Schmidt J.Primary malignant hepatic epithelioid hemangioendothelioma:a comprehensive review of the literature with emphasis on the surgical therapy.Cancer 2006;107:2108-2121[PMID:17019735 DOI:10.1002/cncr.22225]
14 Makhlouf HR,Ishak KG,Goodman ZD.Epithelioid hemangioendothelioma of the liver:a clinicopathologic study of 137 cases.Cancer 1999;85:562-582[PMID:10091730 DOI:10.1002/(SICI)1097-0142(19990201)85:33.0.CO;2-T]
15 Demetris AJ,Minervini M,Raikow RB,Lee RG.Hepatic epithelioid hemangioendothelioma:biological questions based on pattern of recurrence in an allograft and tumor immunophenotype.Am J Surg Pathol1997;21:263-270[PMID:9060595 DOI:10.1097/00000478-199703000-00001]
16 Doyle LA,Fletcher CD,Hornick JL.Nuclear Expression of CAMTA1 Distinguishes Epithelioid Hemangioendothelioma From Histologic Mimics.Am J Surg Pathol 2016;40:94-102[PMID:26414223DOI:10.1097/PAS.0000000000000511]
17 Shibuya R,Matsuyama A,Shiba E,Harada H,Yabuki K,Hisaoka M.CAMTA1 is a useful immunohistochemical marker for diagnosing epithelioid haemangioendothelioma.Histopathology 2015;67:827-835[PMID:25879300 DOI:10.1111/his.12713]
18 Bioulac-Sage P,Laumonier H,Laurent C,Blanc JF,Balabaud C.Benign and malignant vascular tumors of the liver in adults.Semin Liver Dis 2008;28:302-314[PMID:18814083 DOI:10.1055/s-0028-1085098]
19 Briongos-Figuero LS,Zamora-Martínez T.A rare vascular tumor of the liver.Clin Gastroenterol Hepatol2015;13:e46-e47[PMID:25496814 DOI:10.1016/j.cgh.2014.11.031]
20 Ehman EC,Torbenson MS,Wells ML,Welch BT,Thompson SM,Garg I,Venkatesh SK.Hepatic tumors of vascular origin:imaging appearances.Abdom Radiol(NY)2018;43:1978-1990[PMID:29159525 DOI:10.1007/s00261-017-1401-3]
21 Lai Q,Feys E,Karam V,Adam R,Klempnauer J,Oliverius M,Mazzaferro V,Pascher A,Remiszewski P,Isoniemi H,Pirenne J,Foss A,Ericzon BG,Markovic S,Lerut JP;European Liver Intestine Transplant Association(ELITA).Hepatic Epithelioid Hemangioendothelioma and Adult Liver Transplantation:Proposal for a Prognostic Score Based on the Analysis of the ELTR-ELITA Registry.Transplantation2017;101:555-564[PMID:28212256 DOI:10.1097/TP.0000000000001603]
22 Lerut JP,Weber M,Orlando G,Dutkowski P.Vascular and rare liver tumors:a good indication for liver transplantation?J Hepatol 2007;47:466-475[PMID:17697721 DOI:10.1016/j.jhep.2007.07.005]
23 Jung DH,Hwang S,Hong SM,Kim KH,Lee YJ,Ahn CS,Moon DB,Ha TY,Song GW,Park GC,Yu E,Lee SG.Clinicopathological Features and Prognosis of Hepatic Epithelioid Hemangioendothelioma After Liver Resection and Transplantation.Ann Transplant 2016;21:784-790[PMID:28031549 DOI:10.12659/AOT.901172]
24 Galv?o FH,Bakonyi-Neto A,Machado MA,Farias AQ,Mello ES,Diz ME,Machado MC.Interferon alpha-2B and liver resection to treat multifocal hepatic epithelioid hemangioendothelioma:a relevant approach to avoid liver transplantation.Transplant Proc 2005;37:4354-4358[PMID:16387119 DOI:10.1016/j.transproceed.2005.11.022]
25 Cardinal J,de Vera ME,Marsh JW,Steel JL,Geller DA,Fontes P,Nalesnik M,Gamblin TC.Treatment of hepatic epithelioid hemangioendothelioma:a single-institution experience with 25 cases.Arch Surg2009;144:1035-1039[PMID:19917940 DOI:10.1001/archsurg.2009.121]
26 Rodriguez JA,Becker NS,O'Mahony CA,Goss JA,Aloia TA.Long-term outcomes following liver transplantation for hepatic hemangioendothelioma:the UNOS experience from 1987 to 2005.JGastrointest Surg 2008;12:110-116[PMID:17710508 DOI:10.1007/s11605-007-0247-3]
27 Desie N,Van Raemdonck DE,Ceulemans LJ,Nevens F,Verslype C,Vansteenbergen W,Pirenne J,Monbaliu D,Roskams T,Verbeken EK,Neyrinck AP,Dupont LJ,Yserbyt J,Verleden GM,Vos R.Combined or Serial Liver and Lung Transplantation for Epithelioid Hemangioendothelioma:A Case Series.Am J Transplant 2015;15:3247-3254[PMID:26288367 DOI:10.1111/ajt.13430]
28 Semenisty V,Naroditsky I,Keidar Z,Bar-Sela G.Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option:case report and review of anti-angiogenic treatment options.BMC Cancer 2015;15:402[PMID:25967676 DOI:10.1186/s12885-015-1395-6]
29 Chevreau C,Le Cesne A,Ray-Coquard I,Italiano A,Cioffi A,Isambert N,Robin YM,Fournier C,Clisant S,Chaigneau L,Bay JO,Bompas E,Gauthier E,Blay JY,Penel N.Sorafenib in patients with progressive epithelioid hemangioendothelioma:a phase 2 study by the French Sarcoma Group(GSF/GETO).Cancer 2013;119:2639-2644[PMID:23589078 DOI:10.1002/cncr.28109]
30 Agulnik M,Yarber JL,Okuno SH,von Mehren M,Jovanovic BD,Brockstein BE,Evens AM,Benjamin RS.An open-label,multicenter,phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas.Ann Oncol 2013;24:257-263[PMID:22910841 DOI:10.1093/annonc/mds237]
31 Soape MP,Verma R,Payne JD,Wachtel M,Hardwicke F,Cobos E.Treatment of Hepatic Epithelioid Hemangioendothelioma:Finding Uses for Thalidomide in a New Era of Medicine.Case Rep Gastrointest Med 2015;2015:326795[PMID:26167310 DOI:10.1155/2015/326795]
32 Pallotti MC,Nannini M,Agostinelli C,Leoni S,Scioscio VD,Mandrioli A,Lolli C,Saponara M,Pileri S,Bolondi L,Biasco G,Pantaleo MA.Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma.World J Gastroenterol 2014;20:7049-7054[PMID:24944501 DOI:10.3748/wjg.v20.i22.7049]
33 Stiles JM,Amaya C,Rains S,Diaz D,Pham R,Battiste J,Modiano JF,Kokta V,Boucheron LE,Mitchell DC,Bryan BA.Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.PLoS One 2013;8:e60021[PMID:23555867 DOI:10.1371/journal.pone.0060021]
34 Lakkis Z,Kim S,Delabrousse E,Jary M,Nguyen T,Mantion G,Heyd B,Lassabe C,Borg C.Metronomic cyclophosphamide:an alternative treatment for hepatic epithelioid hemangioendothelioma.JHepatol 2013;58:1254-1257[PMID:23402747 DOI:10.1016/j.jhep.2013.01.043]
35 Chaudhary P,Bhadana U,Singh RA,Ahuja A.Primary hepatic angiosarcoma.Eur J Surg Oncol 2015;41:1137-1143[PMID:26008857 DOI:10.1016/j.ejso.2015.04.022]
36 Coulier B,Pierard F,Gielen I,Maldague P.Hepatic angiosarcoma occurring 65 years after thorium dioxide(Thorotrast)exposure:imaging,surgical and histo-pathologic findings of a historical case.JBR-BTR 2014;97:254-258[PMID:25603638]
37 Collins JJ,Jammer B,Sladeczek FM,Bodnar CM,Salomon SS.Surveillance for angiosarcoma of the liver among vinyl chloride workers.J Occup Environ Med 2014;56:1207-1209[PMID:25376416 DOI:10.1097/JOM.0000000000000247]
38 Huang NC,Wann SR,Chang HT,Lin SL,Wang JS,Guo HR.Arsenic,vinyl chloride,viral hepatitis,and hepatic angiosarcoma:a hospital-based study and review of literature in Taiwan.BMC Gastroenterol2011;11:142[PMID:22200164 DOI:10.1186/1471-230X-11-142]
39 Wang ZB,Wei LX.[Primary hepatic angiosarcoma:a clinical and pathological analysis].Zhonghua Bing Li Xue Za Zhi 2013;42:376-380[PMID:24060070 DOI:10.3760/cma.j.issn.0529-5807.2013.06.005]
40 Ito Y,Kojiro M,Nakashima T,Mori T.Pathomorphologic characteristics of 102 cases of thorotrast-related hepatocellular carcinoma,cholangiocarcinoma,and hepatic angiosarcoma.Cancer 1988;62:1153-1162[PMID:2457426 DOI:10.1002/1097-0142(19880915)62:63.0.CO;2-I]
41 Miettinen M,Wang ZF,Paetau A,Tan SH,Dobi A,Srivastava S,Sesterhenn I.ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma.Am J Surg Pathol 2011;35:432-441[PMID:21317715 DOI:10.1097/PAS.0b013e318206b67b]
42 Hollstein M,Marion MJ,Lehman T,Welsh J,Harris CC,Martel-Planche G,Kusters I,Montesano R.p53mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers.Carcinogenesis1994;15:1-3[PMID:8293534 DOI:10.1093/carcin/15.1.1]
43 Przygodzki RM,Finkelstein SD,Keohavong P,Zhu D,Bakker A,Swalsky PA,Soini Y,Ishak KG,Bennett WP.Sporadic and Thorotrast-induced angiosarcomas of the liver manifest frequent and multiple point mutations in K-ras-2.Lab Invest 1997;76:153-159[PMID:9010458 DOI:10.1121/1.417965]
44 Zhu YP,Chen YM,Matro E,Chen RB,Jiang ZN,Mou YP,Hu HJ,Huang CJ,Wang GY.Primary hepatic angiosarcoma:A report of two cases and literature review.World J Gastroenterol 2015;21:6088-6096[PMID:26019478 DOI:10.3748/wjg.v21.i19.6088]
45 Leowardi C,Hormann Y,Hinz U,Wente MN,Hallscheidt P,Flechtenmacher C,Buchler MW,Friess H,Schwarzbach MH.Ruptured angiosarcoma of the liver treated by emergency catheter-directed embolization.World J Gastroenterol 2006;12:804-808[PMID:16521200 DOI:10.3748/wjg.v12.i5.804]
46 Alves VAF,Rimola J.Malignant Vascular Tumors of the Liver in Adults.Semin Liver Dis 2019;39:1-12[PMID:30536289 DOI:10.1055/s-0038-1676120]
47 Wong JW,Bedard YC.Fine-needle aspiration biopsy of hepatic angiosarcoma:report of a case with immunocytochemical findings.Diagn Cytopathol 1992;8:380-383[PMID:1638939 DOI:10.1002/dc.2840080416]
48 Wang L,Lv K,Chang XY,Xia Y,Yang ZY,Jiang YX,Dai Q,Tan L,Li JC.Contrast-enhanced ultrasound study of primary hepatic angiosarcoma:a pitfall of non-enhancement.Eur J Radiol 2012;81:2054-2059[PMID:21737220 DOI:10.1016/j.ejrad.2011.06.026]
49 Park YS,Kim JH,Kim KW,Lee IS,Yoon HK,Ko GY,Sung KB.Primary hepatic angiosarcoma:imaging findings and palliative treatment with transcatheter arterial chemoembolization or embolization.Clin Radiol 2009;64:779-785[PMID:19589416 DOI:10.1016/j.crad.2009.02.019]
50 Kamatani T,Iguchi H,Okada T,Yamazaki H,Tsunoda H,Watanabe M,Oda M,Ohbu M,Yokomori H.Co-registered positron emission tomography/computed tomography and gadolinium-ethoxybenzyldiethylenetriamine pentaacetic acid magnetic resonance imaging features of multiple angiosarcoma of the liver.Hepatol Res 2014;44:E297-E303[PMID:24147907 DOI:10.1111/hepr.12261]
51 Bruegel M,Muenzel D,Waldt S,Specht K,Rummeny EJ.Hepatic angiosarcoma:cross-sectional imaging findings in seven patients with emphasis on dynamic contrast-enhanced and diffusion-weighted MRI.Abdom Imaging 2013;38:745-754[PMID:23223833 DOI:10.1007/s00261-012-9967-2]
52 Maeda T,Tateishi U,Hasegawa T,Ojima H,Arai Y,Sugimura K.Primary hepatic angiosarcoma on coregistered FDG PET and CT images.AJR Am J Roentgenol 2007;188:1615-1617[PMID:17515384DOI:10.2214/AJR.05.0830]
53 Li DB,Si XY,Wan T,Zhou YM.A pooled analysis of treatment and prognosis of hepatic angiosarcoma in adults.Hepatobiliary Pancreat Dis Int 2018;17:198-203[PMID:29724676 DOI:10.1016/j.hbpd.2018.04.005]
54 Lin YH,Lin CC,Concejero AM,Yong CC,Kuo FY,Wang CC.Surgical experience of adult primary hepatic sarcomas.World J Surg Oncol 2015;13:87[PMID:25880743 DOI:10.1186/s12957-015-0489-6]
55 Orlando G,Adam R,Mirza D,Soderdahl G,Porte RJ,Paul A,Burroughs AK,Seiler CA,Colledan M,Graziadei I,Garcia Valdecasas JC,Pruvot FR,Karam V,Lerut J.Hepatic hemangiosarcoma:an absolute contraindication to liver transplantation--the European Liver Transplant Registry experience.Transplantation 2013;95:872-877[PMID:23354302 DOI:10.1097/TP.0b013e318281b902]
56 Husted TL,Neff G,Thomas MJ,Gross TG,Woodle ES,Buell JF.Liver transplantation for primary or metastatic sarcoma to the liver.Am J Transplant 2006;6:392-397[PMID:16426326 DOI:10.1111/j.1600-6143.2005.01179.x]
57 Huang NC,Kuo YC,Chiang JC,Hung SY,Wang HM,Hung YM,Chang YT,Wann SR,Chang HT,Wang JS,Ho SY,Guo HR.Hepatic angiosarcoma may have fair survival nowadays.Medicine(Baltimore)2015;94:e816[PMID:25984668 DOI:10.1097/MD.0000000000000816]
58 Kim HR,Rha SY,Cheon SH,Roh JK,Park YN,Yoo NC.Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma.Ann Oncol 2009;20:780-787[PMID:19179547 DOI:10.1093/annonc/mdn702]
59 Asmane I,Litique V,Heymann S,Marcellin L,Métivier AC,Duclos B,Bergerat JP,Kurtz JE.Adriamycin,cisplatin,ifosfamide and paclitaxel combination as front-line chemotherapy for locally advanced and metastatic angiosarcoma.Analysis of three case reports and review of the literature.Anticancer Res 2008;28:3041-3045[PMID:19031953 DOI:10.1097/CAD.0b013e32830c2380]
60 Pierce DB,Johnson GE,Monroe E,Loggers ET,Jones RL,Pollack SM,Padia SA.Safety and Efficacy Outcomes of Embolization in Hepatic Sarcomas.AJR Am J Roentgenol 2018;210:175-182[PMID:29090997 DOI:10.2214/AJR.16.17573]
61 Young RJ,Woll PJ.Anti-angiogenic therapies for the treatment of angiosarcoma:a clinical update.Memo2017;10:190-193[PMID:29250195 DOI:10.1007/s12254-017-0365-x]
62 Mitsui F,Aikata H,Hashimoto Y,Nagaoki Y,Kimura Y,Katamura Y,Kawaoka T,Takaki S,Hiraga N,Tsuge M,Waki K,Hiramatsu A,Imamura M,Kawakami Y,Takahashi S,Arihiro K,Chayama K.A first case of hepatic angiosarcoma treated with recombinant interleukin-2.Hiroshima J Med Sci 2011;60:91-96[PMID:22389954 DOI:10.5980/jpnjurol.103.697]
63 Sindhu S,Gimber LH,Cranmer L,McBride A,Kraft AS.Angiosarcoma treated successfully with antiPD-1 therapy-a case report.J Immunother Cancer 2017;5:58[PMID:28716069 DOI:10.1186/s40425-017-0263-0]
64 Pandiaraja J,Subramanian V.A Case of Primary Hemangiopericytoma of Liver.J Med Sci 2015;35:169-172[DOI:10.4103/1011-4564.163825]
65 Guillou L,Fletcher JA,Fletcher CD,Mandahl N,Fletcher CDM,Unni KK,Mertens F.Extrapleural solitary fibrous tumor and hemangiopericytoma.Fletcher CDM,Unni KK,Mertens F.WHO classification of tumours:Pathology and genetics of tumours of soft tissue and bone.Lyon:IARC Press 2002;86-90
66 Lehmann C,Mourra N,Tubiana JM,ArrivéL.[Solitary fibrous tumor of the liver].J Radiol 2006;87:139-142[PMID:16484938 DOI:10.1016/S0221-0363(06)73986-5]
67 Liang YM,Li XH,LüYL,Zhong M.[Morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors].Zhonghua Yi Xue Za Zhi 2005;85:96-100[PMID:15774214 DOI:10.3760/j:issn:0376-2491.2005.02.007]
68 Zimmermann A.Solitary fibrous tumor/hemangiopericytoma of the liver.In:Tumors and tumor-like lesions of the hepatobiliary tract.Springer,Cham 2017;1057-1067[DOI:10.1007/978-3-319-26956-6_61]
69 Caruso S,Gruttadauria S,Minervini MI,Miraglia R,Milazzo M,Luca A,Gridelli B.Primary hemangiopericytoma of the liver:sonographic findings.J Clin Ultrasound 2009;37:305-307[PMID:19253347 DOI:10.1002/jcu.20567]
70 Adams J,Lodge JP,Parker D.Liver transplantation for metastatic hemangiopericytoma associated with hypoglycemia.Transplantation 1999;67:488-489[PMID:10030302 DOI:10.1097/00007890-199902150-00027]
71 Flores-Stadler EM,Chou P,Walterhouse D,Bourtsos E,Gonzalez-Crussi F.Hemangiopericytoma of the liver:immunohistochemical observations,expression of angiogenic factors,and review of the literature.JPediatr Hematol Oncol 1997;19:449-454[PMID:9329468 DOI:10.1097/00043426-199709000-00008]
72 Uemura S,Kuratsu J,Hamada J,Yoshioka S,Kochi M,Ushio Y,Nakahara T,Kishida K.Effect of radiation therapy against intracranial hemangiopericytoma.Neurol Med Chir(Tokyo)1992;32:328-332[PMID:1381057 DOI:10.2176/nmc.32.328]
73 Beadle GF,Hillcoat BL.Treatment of advanced malignant hemangiopericytoma with combination adriamycin and DTIC:a report of four cases.J Surg Oncol 1983;22:167-170[PMID:6682161 DOI:10.1002/jso.2930220306]
74 Galanis E,Buckner JC,Scheithauer BW,Kimmel DW,Schomberg PJ,Piepgras DG.Management of recurrent meningeal hemangiopericytoma.Cancer 1998;82:1915-1920[PMID:9587125 DOI:10.1002/(SICI)1097-0142(19980515)82:103.0.CO;2-W]
75 Chamberlain MC,Glantz MJ.Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma.Neurosurgery 2008;63:720-6;author reply 726-7[PMID:18981882 DOI:10.1227/01.NEU.0000325494.69836.51]
76 Constantinidou A,Jones RL,Scurr M,Al-Muderis O,Judson I.Systemic therapy in solitary fibrous tumour[abstract#39407].15th Connective Tissue Oncologic Society Annual Meeting,Miami,FL.2009
77 Park MS,Patel SR,Ludwig JA,Trent JC,Conrad CA,Lazar AJ,Wang WL,Boonsirikamchai P,Choi H,Wang X,Benjamin RS,Araujo DM.Activity of temozolomide and bevacizumab in the treatment of locally advanced,recurrent,and metastatic hemangiopericytoma and malignant solitary fibrous tumor.Cancer 2011;117:4939-4947[PMID:21480200 DOI:10.1002/cncr.26098]
78 Casali PG,Stacchiotti S,Palassini E,Marrari A,Morosi C,Messina A.Evaluation of the antitumor activity of sunitinib malate(SM)in solitary fibrous tumor(SFT).J Clin Oncol 2009;27(15S);abstr 10571
79 Maki RG,D'Adamo DR,Keohan ML,Saulle M,Schuetze SM,Undevia SD,Livingston MB,Cooney MM,Hensley ML,Mita MM,Takimoto CH,Kraft AS,Elias AD,Brockstein B,Blachère NE,Edgar MA,Schwartz LH,Qin LX,Antonescu CR,Schwartz GK.Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.J Clin Oncol 2009;27:3133-3140[PMID:19451436 DOI:10.1200/JCO.2008.20.4495]
80 Bonetti F,Pea M,Martignoni G,Zamboni G.PEC and sugar.Am J Surg Pathol 1992;16:307-308[PMID:1599021 DOI:10.1097/00000478-199203000-00013]
81 Folpe AL,Kwiatkowski DJ.Perivascular epithelioid cell neoplasms:pathology and pathogenesis.Hum Pathol 2010;41:1-15[PMID:19604538 DOI:10.1016/j.humpath.2009.05.011]
82 Parfitt JR,Bella AJ,Izawa JI,Wehrli BM.Malignant neoplasm of perivascular epithelioid cells of the liver.Arch Pathol Lab Med 2006;130:1219-1222[PMID:16879028 DOI:10.1043/1543-2165(2006)130[1219:MNOPEC]2.0.CO;2]
83 Bonetti F,Martignoni G,Colato C,Manfrin E,Gambacorta M,Faleri M,Bacchi C,Sin VC,Wong NL,Coady M,Chan JK.Abdominopelvic sarcoma of perivascular epithelioid cells.Report of four cases in young women,one with tuberous sclerosis.Mod Pathol 2001;14:563-568[PMID:11406657 DOI:10.1038/modpathol.3880351]
84 Zhao LJ,Yang YJ,Wu H,Huang SM,Liu K.Perivascular epithelioid cell tumor of the liver:a case report and literature review.Eur Rev Med Pharmacol Sci 2013;17:1665-1668[PMID:23832736 DOI:10.1345/aph.1R620]
85 Harris GC,McCulloch TA,Perks G,Fisher C.Malignant perivascular epithelioid cell tumour("PEComa")of soft tissue:a unique case.Am J Surg Pathol 2004;28:1655-1658[PMID:15577688 DOI:10.1097/00000478-200412000-00017]
86 Lehman NL.Malignant PEComa of the skull base.Am J Surg Pathol 2004;28:1230-1232[PMID:15316324 DOI:10.1097/01.pas.0000128668.34934.81]
87 Sadeghi S,Krigman H,Maluf H.Perivascular epithelioid clear cell tumor of the common bile duct.Am JSurg Pathol 2004;28:1107-1110[PMID:15252321 DOI:10.1097/01.pas.0000116831.81882.d0]
88 Silva EG,Deavers MT,Bodurka DC,Malpica A.Uterine epithelioid leiomyosarcomas with clear cells:reactivity with HMB-45 and the concept of PEComa.Am J Surg Pathol 2004;28:244-249[PMID:15043315 DOI:10.1097/00000478-200402000-00013]
89 Tsui WM,Colombari R,Portmann BC,Bonetti F,Thung SN,Ferrell LD,Nakanuma Y,Snover DC,Bioulac-Sage P,Dhillon AP.Hepatic angiomyolipoma:a clinicopathologic study of 30 cases and delineation of unusual morphologic variants.Am J Surg Pathol 1999;23:34-48[PMID:9888702 DOI:10.1097/00000478-199901000-00004]
90 Martignoni G,Pea M,Reghellin D,Zamboni G,Bonetti F.PEComas:the past,the present and the future.Virchows Arch 2008;452:119-132[PMID:18080139 DOI:10.1007/s00428-007-0509-1]
91 Pan CC,Chung MY,Ng KF,Liu CY,Wang JS,Chai CY,Huang SH,Chen PC,Ho DM.Constant allelic alteration on chromosome 16p(TSC2 gene)in perivascular epithelioid cell tumour(PEComa):genetic evidence for the relationship of PEComa with angiomyolipoma.J Pathol 2008;214:387-393[PMID:18085521 DOI:10.1002/path.2289]
92 Zhang X,Wang L,Jiang Y,Wan Z,Li W,Yao C,Geng Z,Lv Y.Hepatic perivascular epithelioid cell tumors-not otherwise specified:a case report.Nan Fang Yi Ke Da Xue Xue Bao 2014;34:1-4[PMID:24463106]
93 Folpe AL,Mentzel T,Lehr HA,Fisher C,Balzer BL,Weiss SW.Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin:a clinicopathologic study of 26 cases and review of the literature.Am J Surg Pathol 2005;29:1558-1575[PMID:16327428 DOI:10.1097/01.pas.0000173232.22117.37]
94 Petrolla AA,Xin W.Hepatic angiomyolipoma.Arch Pathol Lab Med 2008;132:1679-1682[PMID:18834230 DOI:10.1043/1543-2165(2008)132[1679:HA]2.0.CO;2]
95 Fadare O,Parkash V,Yilmaz Y,Mariappan MR,Ma L,Hileeto D,Qumsiyeh MB,Hui P.Perivascular epithelioid cell tumor(PEComa)of the uterine cervix associated with intraabdominal"PEComatosis":Aclinicopathological study with comparative genomic hybridization analysis.World J Surg Oncol 2004;2:35[PMID:15494070 DOI:10.1186/1477-7819-2-35]
96 Zavala-Pompa A,Folpe AL,Jimenez RE,Lim SD,Cohen C,Eble JN,Amin MB.Immunohistochemical study of microphthalmia transcription factor and tyrosinase in angiomyolipoma of the kidney,renal cell carcinoma,and renal and retroperitoneal sarcomas:comparative evaluation with traditional diagnostic markers.Am J Surg Pathol 2001;25:65-70[PMID:11145253 DOI:10.1097/00000478-200101000-00007]
97 Priola AM,Priola SM,Cataldi A,Marci V,Fava C.Acute abdomen as an unusual presentation of hepatic PEComa.A case report.Tumori 2009;95:123-128[PMID:19366072 DOI:10.1177/030089160909500124]
98 Son HJ,Kang DW,Kim JH,Han HY,Lee MK.Hepatic perivascular epithelioid cell tumor(PEComa):a case report with a review of literatures.Clin Mol Hepatol 2017;23:80-86[PMID:28288506 DOI:10.3350/cmh.2016.0034]
99 Stone CH,Lee MW,Amin MB,Yaziji H,Gown AM,Ro JY,Têtu B,Paraf F,Zarbo RJ.Renal angiomyolipoma:further immunophenotypic characterization of an expanding morphologic spectrum.Arch Pathol Lab Med 2001;125:751-758[PMID:11371226 DOI:10.1016/j.susc.2006.09.001]
100 Tan Y,Zhang H,Xiao EH.Perivascular epithelioid cell tumour:dynamic CT,MRI and clinicopathological characteristics--analysis of 32 cases and review of the literature.Clin Radiol 2013;68:555-561[PMID:23245276 DOI:10.1016/j.crad.2012.10.021]
101 Maebayashi T,Abe K,Aizawa T,Sakaguchi M,Ishibashi N,Abe O,Takayama T,Nakayama H,Matsuoka S,Nirei K,Nakamura H,Ogawa M,Sugitani M.Improving recognition of hepatic perivascular epithelioid cell tumor:Case report and literature review.World J Gastroenterol 2015;21:5432-5441[PMID:25954119 DOI:10.3748/wjg.v21.i17.5432]
102 Tirumani SH,Shinagare AB,Hargreaves J,Jagannathan JP,Hornick JL,Wagner AJ,Ramaiya NH.Imaging features of primary and metastatic malignant perivascular epithelioid cell tumors.AJR Am JRoentgenol 2014;202:252-258[PMID:24450662 DOI:10.2214/AJR.13.10909]
103 Kumasaka S,Arisaka Y,Tokue A,Higuchi T,Nakajima T,Tsushima Y.A case of multiple hepatic angiomyolipomas with high(18)?F-fluorodeoxyglucose uptake.BMC Med Imaging 2014;14:17[PMID:24885757 DOI:10.1186/1471-2342-14-17]
104 Deng YF,Lin Q,Zhang SH,Ling YM,He JK,Chen XF.Malignant angiomyolipoma in the liver:a case report with pathological and molecular analysis.Pathol Res Pract 2008;204:911-918[PMID:18723294DOI:10.1016/j.prp.2008.06.007]
105 Khaja F,Carilli A,Baidas S,Sriharan A,Norford S.PEComa:A Perivascular Epithelioid Cell Tumor in the Liver-A Case Report and Review of the Literature.Case Rep Med 2013;2013:904126[PMID:24489554 DOI:10.1155/2013/904126]
106 Kirste S,Kayser G,Zipfel A,Grosu AL,Brunner T.Unresectable hepatic PEComa:a rare malignancy treated with stereotactic body radiation therapy(SBRT)followed by complete resection.Radiat Oncol2018;13:28[PMID:29463266 DOI:10.1186/s13014-018-0974-5]
107 Guan H,Zou Y,Lv Y,Wang C.Hepatic perivascular epithelioid cell tumor treated by transarterial embolization plus radiofrequency ablation:A case report and literature review.Medicine(Baltimore)2017;96:e6969[PMID:28562547 DOI:10.1097/MD.0000000000006969]
108 Bergamo F,Maruzzo M,Basso U,Montesco MC,Zagonel V,Gringeri E,Cillo U.Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor(PEComa).World J Surg Oncol 2014;12:46[PMID:24575738 DOI:10.1186/1477-7819-12-46]
109 Bleeker JS,Quevedo JF,Folpe AL."Malignant"perivascular epithelioid cell neoplasm:risk stratification and treatment strategies.Sarcoma 2012;2012:541626[PMID:22619565 DOI:10.1155/2012/541626]
110 Wagner AJ,Malinowska-Kolodziej I,Morgan JA,Qin W,Fletcher CD,Vena N,Ligon AH,Antonescu CR,Ramaiya NH,Demetri GD,Kwiatkowski DJ,Maki RG.Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors:targeting the pathogenic activation of mTORC1 in tumors.J Clin Oncol 2010;28:835-840[PMID:20048174 DOI:10.1200/JCO.2009.25.2981]
111 Tacconi D,Vergori A,Lapini L,Magnolfi A,Carnevali A,Caremani M.Hepatic Kaposi's sarcoma in a patient affected by AIDS:Correlation between histology and imaging.J Ultrasound 2012;15:215-219[PMID:23730384 DOI:10.1016/j.jus.2012.10.004]
112 Giuliani M,Cordiali-Fei P,Castilletti C,Di Carlo A,Palamara G,Boros S,Rezza G.Incidence of human herpesvirus 8(HHV-8)infection among HIV-uninfected individuals at high risk for sexually transmitted infections.BMC Infect Dis 2007;7:143[PMID:18053246 DOI:10.1186/1471-2334-7-143]
113 Lodi S,Guiguet M,Costagliola D,Fisher M,de Luca A,Porter K;CASCADE Collaboration.Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion.J Natl Cancer Inst 2010;102:784-792[PMID:20442214 DOI:10.1093/jnci/djq134]
114 Bhutani M,Polizzotto MN,Uldrick TS,Yarchoan R.Kaposi sarcoma-associated herpesvirus-associated malignancies:epidemiology,pathogenesis,and advances in treatment.Semin Oncol 2015;42:223-246[PMID:25843728 DOI:10.1053/j.seminoncol.2014.12.027]
115 Shiels MS,Pfeiffer RM,Gail MH,Hall HI,Li J,Chaturvedi AK,Bhatia K,Uldrick TS,Yarchoan R,Goedert JJ,Engels EA.Cancer burden in the HIV-infected population in the United States.J Natl Cancer Inst 2011;103:753-762[PMID:21483021 DOI:10.1093/jnci/djr076]
116 Antman K,Chang Y.Kaposi's sarcoma.N Engl J Med 2000;342:1027-1038[PMID:10749966 DOI:10.1056/NEJM200004063421407]
117 Russo JJ,Bohenzky RA,Chien MC,Chen J,Yan M,Maddalena D,Parry JP,Peruzzi D,Edelman IS,Chang Y,Moore PS.Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus(HHV8).Proc Natl Acad Sci USA 1996;93:14862-14867[PMID:8962146 DOI:10.1073/pnas.93.25.14862]
118 Mercader M,Taddeo B,Panella JR,Chandran B,Nickoloff BJ,Foreman KE.Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells.Am J Pathol 2000;156:1961-1971[PMID:10854219 DOI:10.1016/S0002-9440(10)65069-9]
119 Friborg J,Kong W,Hottiger MO,Nabel GJ.p53 inhibition by the LANA protein of KSHV protects against cell death.Nature 1999;402:889-894[PMID:10622254 DOI:10.1038/47266]
120 Nakamura T,Mizuno S.The discovery of hepatocyte growth factor(HGF)and its significance for cell biology,life sciences and clinical medicine.Proc Jpn Acad Ser B Phys Biol Sci 2010;86:588-610[PMID:20551596 DOI:10.2183/pjab.86.588]
121 Hong YK,Foreman K,Shin JW,Hirakawa S,Curry CL,Sage DR,Libermann T,Dezube BJ,Fingeroth JD,Detmar M.Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus.Nat Genet 2004;36:683-685[PMID:15220917 DOI:10.1038/ng1383]
122 Hammock L,Reisenauer A,Wang W,Cohen C,Birdsong G,Folpe AL.Latency-associated nuclear antigen expression and human herpesvirus-8 polymerase chain reaction in the evaluation of Kaposi sarcoma and other vascular tumors in HIV-positive patients.Mod Pathol 2005;18:463-468[PMID:15578080 DOI:10.1038/modpathol.3800221]
123 Schneiderman DJ,Arenson DM,Cello JP,Margaretten W,Weber TE.Hepatic disease in patients with the acquired immune deficiency syndrome(AIDS).Hepatology 1987;7:925-930[PMID:2820858 DOI:10.1002/hep.1840070522]
124 Read PJ,Lucas S,Morris S,Kulasegaram R.Immune reconstitution inflammatory syndrome Kaposi sarcoma in the liver manifesting as acute obstructive hepatitis:another potential role for montelukast?Int JSTD AIDS 2013;24:156-158[PMID:24400347 DOI:10.1177/0956462412472819]
125 Hammerman AM,Kotner LM,Doyle TB.Periportal contrast enhancement on CT scans of the liver.AJRAm J Roentgenol 1991;156:313-315[PMID:1898805 DOI:10.2214/ajr.156.2.1898805]
126 Valls C,Ca?as C,Turell LG,Pruna X.Hepatosplenic AIDS-related Kaposi's sarcoma.Gastrointest Radiol1991;16:342-344[PMID:1936779 DOI:10.1007/BF01887385]
127 Nasti G,Talamini R,Antinori A,Martellotta F,Jacchetti G,Chiodo F,Ballardini G,Stoppini L,Di Perri G,Mena M,Tavio M,Vaccher E,D'Arminio Monforte A,Tirelli U;AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive from Antiretrovirals.AIDS-related Kaposi's Sarcoma:evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals.J Clin Oncol 2003;21:2876-2882[PMID:12885804 DOI:10.1200/JCO.2003.10.162]
128 Maskew M,Fox MP,van Cutsem G,Chu K,Macphail P,Boulle A,Egger M,Africa FI.Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma:a cohort study.PLoS One 2013;8:e64392[PMID:23755122 DOI:10.1371/journal.pone.0064392]
129 Donato V,Guarnaccia R,Dognini J,de Pascalis G,Caruso C,Bellagamba R,Morrone A.Radiation therapy in the treatment of HIV-related Kaposi's sarcoma.Anticancer Res 2013;33:2153-2157[PMID:23645769]
130 Gbabe OF,Okwundu CI,Dedicoat M,Freeman EE.Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.Cochrane Database Syst Rev 2014;CD003256[PMID:25221796 DOI:10.1002/14651858.CD003256.pub2]
131 Van Leer-Greenberg B,Kole A,Chawla S.Hepatic Kaposi sarcoma:A case report and review of the literature.World J Hepatol 2017;9:171-179[PMID:28217255 DOI:10.4254/wjh.v9.i4.171]
132 Stewart S,Jablonowski H,Goebel FD,Arasteh K,Spittle M,Rios A,Aboulafia D,Galleshaw J,Dezube BJ.Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma.International Pegylated Liposomal Doxorubicin Study Group.J Clin Oncol 1998;16:683-691[PMID:9469358 DOI:10.1200/JCO.1998.16.2.683]
133 Grünaug M,Bogner JR,Loch O,Goebel FD.Liposomal doxorubicin in pulmonary Kaposi's sarcoma:improved survival as compared to patients without liposomal doxorubicin.Eur J Med Res 1998;3:13-19[PMID:9512962]
134 Gill PS,Wernz J,Scadden DT,Cohen P,Mukwaya GM,von Roenn JH,Jacobs M,Kempin S,Silverberg I,Gonzales G,Rarick MU,Myers AM,Shepherd F,Sawka C,Pike MC,Ross ME.Randomized phase IIItrial of liposomal daunorubicin versus doxorubicin,bleomycin,and vincristine in AIDS-related Kaposi's sarcoma.J Clin Oncol 1996;14:2353-2364[PMID:8708728 DOI:10.1200/JCO.1996.14.8.2353]
135 Martellotta F,Berretta M,Vaccher E,Schioppa O,Zanet E,Tirelli U.AIDS-related Kaposi's sarcoma:state of the art and therapeutic strategies.Curr HIV Res 2009;7:634-638[PMID:19929800 DOI:10.2174/157016209789973619]
136 Gantt S,Casper C.Human herpesvirus 8-associated neoplasms:the roles of viral replication and antiviral treatment.Curr Opin Infect Dis 2011;24:295-301[PMID:21666458 DOI:10.1097/QCO.0b013e3283486d04]
137 La Ferla L,Pinzone MR,Nunnari G,Martellotta F,Lleshi A,Tirelli U,De Paoli P,Berretta M,Cacopardo B.Kaposi's sarcoma in HIV-positive patients:the state of art in the HAART-era.Eur Rev Med Pharmacol Sci 2013;17:2354-2365[PMID:24065230]
138 Gill RM,Buelow B,Mather C,Joseph NM,Alves V,Brunt EM,Liu TC,Makhlouf H,Marginean C,Nalbantoglu I,Sempoux C,Snover DC,Thung SN,Yeh MM,Ferrell LD.Hepatic small vessel neoplasm,a rare infiltrative vascular neoplasm of uncertain malignant potential.Hum Pathol 2016;54:143-151[PMID:27090685 DOI:10.1016/j.humpath.2016.03.018]
139 Behjati S,Tarpey PS,Sheldon H,Martincorena I,Van Loo P,Gundem G,Wedge DC,Ramakrishna M,Cooke SL,Pillay N,Vollan HKM,Papaemmanuil E,Koss H,Bunney TD,Hardy C,Joseph OR,Martin S,Mudie L,Butler A,Teague JW,Patil M,Steers G,Cao Y,Gumbs C,Ingram D,Lazar AJ,Little L,Mahadeshwar H,Protopopov A,Al Sannaa GA,Seth S,Song X,Tang J,Zhang J,Ravi V,Torres KE,Khatri B,Halai D,Roxanis I,Baumhoer D,Tirabosco R,Amary MF,Boshoff C,McDermott U,Katan M,Stratton MR,Futreal PA,Flanagan AM,Harris A,Campbell PJ.Recurrent PTPRB and PLCG1 mutations in angiosarcoma.Nat Genet 2014;46:376-379[PMID:24633157 DOI:10.1038/ng.2921]
140 Antonescu CR,Yoshida A,Guo T,Chang NE,Zhang L,Agaram NP,Qin LX,Brennan MF,Singer S,Maki RG.KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.Cancer Res 2009;69:7175-7179[PMID:19723655 DOI:10.1158/0008-5472.CAN-09-2068]
141 Lewis S,Aljarallah B,Trivedi A,Thung SN.Magnetic resonance imaging of a small vessel hepatic hemangioma in a cirrhotic patient with histopathologic correlation.Clin Imaging 2015;39:702-706[PMID:25748474 DOI:10.1016/j.clinimag.2015.02.007]
142 Joseph NM,Brunt EM,Marginean C,Nalbantoglu I,Snover DC,Thung SN,Yeh MM,Umetsu SE,Ferrell LD,Gill RM.Frequent GNAQ and GNA14 Mutations in Hepatic Small Vessel Neoplasm.Am JSurg Pathol 2018;42:1201-1207[PMID:29975248 DOI:10.1097/PAS.0000000000001110]
143 Walcott-Sapp S,Tang E,Kakar S,Shen J,Hansen P.Resection of the largest reported hepatic small vessel neoplasm.Hum Pathol 2018;78:159-162[PMID:29366622 DOI:10.1016/j.humpath.2018.01.013]
2 Theodosopoulos T,Dellaportas D,Tsangkas A,Tsangkas N,Psychogiou V,Yiallourou A,Polymeneas G,Kondi-Pafiti A.Clinicopathological features and management of hepatic vascular tumors.A 20-year experience in a Greek University Hospital.J BUON 2013;18:1026-1031[PMID:24344033 DOI:10.4103/0973-1482.126493]
3 Weiss SW,Enzinger FM.Epithelioid hemangioendothelioma:a vascular tumor often mistaken for a carcinoma.Cancer 1982;50:970-981[PMID:7093931 DOI:10.1002/1097-0142(19820901)50:53.0.CO;2-Z]
4 Lau K,Massad M,Pollak C,Rubin C,Yeh J,Wang J,Edelman G,Yeh J,Prasad S,Weinberg G.Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement:insights from an internet registry in the study of a rare cancer.Chest 2011;140:1312-1318[PMID:21546438 DOI:10.1378/chest.11-0039]
5 Ishak KG,Sesterhenn IA,Goodman ZD,Rabin L,Stromeyer FW.Epithelioid hemangioendothelioma of the liver:a clinicopathologic and follow-up study of 32 cases.Hum Pathol 1984;15:839-852[PMID:6088383 DOI:10.1016/S0046-8177(84)80145-8]
6 Hsieh MS,Liang PC,Kao YC,Shun CT.Hepatic epithelioid hemangioendothelioma in Taiwan:a clinicopathologic study of six cases in a single institution over a 15-year period.J Formos Med Assoc2010;109:219-227[PMID:20434030 DOI:10.1016/S0929-6646(10)60045-9]
7 Sardaro A,Bardoscia L,Petruzzelli MF,Portaluri M.Epithelioid hemangioendothelioma:an overview and update on a rare vascular tumor.Oncol Rev 2014;8:259[PMID:25992243 DOI:10.4081/oncol.2014.259]
8 Hu HJ,Jin YW,Jing QY,Shrestha A,Cheng NS,Li FY.Hepatic epithelioid hemangioendothelioma:Dilemma and challenges in the preoperative diagnosis.World J Gastroenterol 2016;22:9247-9250[PMID:27895413 DOI:10.3748/wjg.v22.i41.9247]
9 Treska V,Daum O,Svajdler M,Liska V,Ferda J,Baxa J.Hepatic Epithelioid Hemangioendothelioma-a Rare Tumor and Diagnostic Dilemma.In Vivo 2017;31:763-767[PMID:28652454 DOI:10.21873/invivo.11128]
10 Miettinen M,Rikala MS,Rys J,Lasota J,Wang ZF.Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma:an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors.Am J Surg Pathol 2012;36:629-639[PMID:22314185 DOI:10.1097/PAS.0b013e318243555b]
11 Mistry AM,Gorden DL,Busler JF,Coogan AC,Kelly BS.Diagnostic and therapeutic challenges in hepatic epithelioid hemangioendothelioma.J Gastrointest Cancer 2012;43:521-525[PMID:22544493DOI:10.1007/s12029-012-9389-y]
12 Flucke U,Vogels RJ,de Saint Aubain Somerhausen N,Creytens DH,Riedl RG,van Gorp JM,Milne AN,Huysentruyt CJ,Verdijk MA,van Asseldonk MM,Suurmeijer AJ,Bras J,Palmedo G,Groenen PJ,Mentzel T.Epithelioid Hemangioendothelioma:clinicopathologic,immunhistochemical,and molecular genetic analysis of 39 cases.Diagn Pathol 2014;9:131[PMID:24986479 DOI:10.1186/1746-1596-9-131]
13 Mehrabi A,Kashfi A,Fonouni H,Schemmer P,Schmied BM,Hallscheidt P,Schirmacher P,Weitz J,Friess H,Buchler MW,Schmidt J.Primary malignant hepatic epithelioid hemangioendothelioma:a comprehensive review of the literature with emphasis on the surgical therapy.Cancer 2006;107:2108-2121[PMID:17019735 DOI:10.1002/cncr.22225]
14 Makhlouf HR,Ishak KG,Goodman ZD.Epithelioid hemangioendothelioma of the liver:a clinicopathologic study of 137 cases.Cancer 1999;85:562-582[PMID:10091730 DOI:10.1002/(SICI)1097-0142(19990201)85:33.0.CO;2-T]
15 Demetris AJ,Minervini M,Raikow RB,Lee RG.Hepatic epithelioid hemangioendothelioma:biological questions based on pattern of recurrence in an allograft and tumor immunophenotype.Am J Surg Pathol1997;21:263-270[PMID:9060595 DOI:10.1097/00000478-199703000-00001]
16 Doyle LA,Fletcher CD,Hornick JL.Nuclear Expression of CAMTA1 Distinguishes Epithelioid Hemangioendothelioma From Histologic Mimics.Am J Surg Pathol 2016;40:94-102[PMID:26414223DOI:10.1097/PAS.0000000000000511]
17 Shibuya R,Matsuyama A,Shiba E,Harada H,Yabuki K,Hisaoka M.CAMTA1 is a useful immunohistochemical marker for diagnosing epithelioid haemangioendothelioma.Histopathology 2015;67:827-835[PMID:25879300 DOI:10.1111/his.12713]
18 Bioulac-Sage P,Laumonier H,Laurent C,Blanc JF,Balabaud C.Benign and malignant vascular tumors of the liver in adults.Semin Liver Dis 2008;28:302-314[PMID:18814083 DOI:10.1055/s-0028-1085098]
19 Briongos-Figuero LS,Zamora-Martínez T.A rare vascular tumor of the liver.Clin Gastroenterol Hepatol2015;13:e46-e47[PMID:25496814 DOI:10.1016/j.cgh.2014.11.031]
20 Ehman EC,Torbenson MS,Wells ML,Welch BT,Thompson SM,Garg I,Venkatesh SK.Hepatic tumors of vascular origin:imaging appearances.Abdom Radiol(NY)2018;43:1978-1990[PMID:29159525 DOI:10.1007/s00261-017-1401-3]
21 Lai Q,Feys E,Karam V,Adam R,Klempnauer J,Oliverius M,Mazzaferro V,Pascher A,Remiszewski P,Isoniemi H,Pirenne J,Foss A,Ericzon BG,Markovic S,Lerut JP;European Liver Intestine Transplant Association(ELITA).Hepatic Epithelioid Hemangioendothelioma and Adult Liver Transplantation:Proposal for a Prognostic Score Based on the Analysis of the ELTR-ELITA Registry.Transplantation2017;101:555-564[PMID:28212256 DOI:10.1097/TP.0000000000001603]
22 Lerut JP,Weber M,Orlando G,Dutkowski P.Vascular and rare liver tumors:a good indication for liver transplantation?J Hepatol 2007;47:466-475[PMID:17697721 DOI:10.1016/j.jhep.2007.07.005]
23 Jung DH,Hwang S,Hong SM,Kim KH,Lee YJ,Ahn CS,Moon DB,Ha TY,Song GW,Park GC,Yu E,Lee SG.Clinicopathological Features and Prognosis of Hepatic Epithelioid Hemangioendothelioma After Liver Resection and Transplantation.Ann Transplant 2016;21:784-790[PMID:28031549 DOI:10.12659/AOT.901172]
24 Galv?o FH,Bakonyi-Neto A,Machado MA,Farias AQ,Mello ES,Diz ME,Machado MC.Interferon alpha-2B and liver resection to treat multifocal hepatic epithelioid hemangioendothelioma:a relevant approach to avoid liver transplantation.Transplant Proc 2005;37:4354-4358[PMID:16387119 DOI:10.1016/j.transproceed.2005.11.022]
25 Cardinal J,de Vera ME,Marsh JW,Steel JL,Geller DA,Fontes P,Nalesnik M,Gamblin TC.Treatment of hepatic epithelioid hemangioendothelioma:a single-institution experience with 25 cases.Arch Surg2009;144:1035-1039[PMID:19917940 DOI:10.1001/archsurg.2009.121]
26 Rodriguez JA,Becker NS,O'Mahony CA,Goss JA,Aloia TA.Long-term outcomes following liver transplantation for hepatic hemangioendothelioma:the UNOS experience from 1987 to 2005.JGastrointest Surg 2008;12:110-116[PMID:17710508 DOI:10.1007/s11605-007-0247-3]
27 Desie N,Van Raemdonck DE,Ceulemans LJ,Nevens F,Verslype C,Vansteenbergen W,Pirenne J,Monbaliu D,Roskams T,Verbeken EK,Neyrinck AP,Dupont LJ,Yserbyt J,Verleden GM,Vos R.Combined or Serial Liver and Lung Transplantation for Epithelioid Hemangioendothelioma:A Case Series.Am J Transplant 2015;15:3247-3254[PMID:26288367 DOI:10.1111/ajt.13430]
28 Semenisty V,Naroditsky I,Keidar Z,Bar-Sela G.Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option:case report and review of anti-angiogenic treatment options.BMC Cancer 2015;15:402[PMID:25967676 DOI:10.1186/s12885-015-1395-6]
29 Chevreau C,Le Cesne A,Ray-Coquard I,Italiano A,Cioffi A,Isambert N,Robin YM,Fournier C,Clisant S,Chaigneau L,Bay JO,Bompas E,Gauthier E,Blay JY,Penel N.Sorafenib in patients with progressive epithelioid hemangioendothelioma:a phase 2 study by the French Sarcoma Group(GSF/GETO).Cancer 2013;119:2639-2644[PMID:23589078 DOI:10.1002/cncr.28109]
30 Agulnik M,Yarber JL,Okuno SH,von Mehren M,Jovanovic BD,Brockstein BE,Evens AM,Benjamin RS.An open-label,multicenter,phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas.Ann Oncol 2013;24:257-263[PMID:22910841 DOI:10.1093/annonc/mds237]
31 Soape MP,Verma R,Payne JD,Wachtel M,Hardwicke F,Cobos E.Treatment of Hepatic Epithelioid Hemangioendothelioma:Finding Uses for Thalidomide in a New Era of Medicine.Case Rep Gastrointest Med 2015;2015:326795[PMID:26167310 DOI:10.1155/2015/326795]
32 Pallotti MC,Nannini M,Agostinelli C,Leoni S,Scioscio VD,Mandrioli A,Lolli C,Saponara M,Pileri S,Bolondi L,Biasco G,Pantaleo MA.Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma.World J Gastroenterol 2014;20:7049-7054[PMID:24944501 DOI:10.3748/wjg.v20.i22.7049]
33 Stiles JM,Amaya C,Rains S,Diaz D,Pham R,Battiste J,Modiano JF,Kokta V,Boucheron LE,Mitchell DC,Bryan BA.Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.PLoS One 2013;8:e60021[PMID:23555867 DOI:10.1371/journal.pone.0060021]
34 Lakkis Z,Kim S,Delabrousse E,Jary M,Nguyen T,Mantion G,Heyd B,Lassabe C,Borg C.Metronomic cyclophosphamide:an alternative treatment for hepatic epithelioid hemangioendothelioma.JHepatol 2013;58:1254-1257[PMID:23402747 DOI:10.1016/j.jhep.2013.01.043]
35 Chaudhary P,Bhadana U,Singh RA,Ahuja A.Primary hepatic angiosarcoma.Eur J Surg Oncol 2015;41:1137-1143[PMID:26008857 DOI:10.1016/j.ejso.2015.04.022]
36 Coulier B,Pierard F,Gielen I,Maldague P.Hepatic angiosarcoma occurring 65 years after thorium dioxide(Thorotrast)exposure:imaging,surgical and histo-pathologic findings of a historical case.JBR-BTR 2014;97:254-258[PMID:25603638]
37 Collins JJ,Jammer B,Sladeczek FM,Bodnar CM,Salomon SS.Surveillance for angiosarcoma of the liver among vinyl chloride workers.J Occup Environ Med 2014;56:1207-1209[PMID:25376416 DOI:10.1097/JOM.0000000000000247]
38 Huang NC,Wann SR,Chang HT,Lin SL,Wang JS,Guo HR.Arsenic,vinyl chloride,viral hepatitis,and hepatic angiosarcoma:a hospital-based study and review of literature in Taiwan.BMC Gastroenterol2011;11:142[PMID:22200164 DOI:10.1186/1471-230X-11-142]
39 Wang ZB,Wei LX.[Primary hepatic angiosarcoma:a clinical and pathological analysis].Zhonghua Bing Li Xue Za Zhi 2013;42:376-380[PMID:24060070 DOI:10.3760/cma.j.issn.0529-5807.2013.06.005]
40 Ito Y,Kojiro M,Nakashima T,Mori T.Pathomorphologic characteristics of 102 cases of thorotrast-related hepatocellular carcinoma,cholangiocarcinoma,and hepatic angiosarcoma.Cancer 1988;62:1153-1162[PMID:2457426 DOI:10.1002/1097-0142(19880915)62:63.0.CO;2-I]
41 Miettinen M,Wang ZF,Paetau A,Tan SH,Dobi A,Srivastava S,Sesterhenn I.ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma.Am J Surg Pathol 2011;35:432-441[PMID:21317715 DOI:10.1097/PAS.0b013e318206b67b]
42 Hollstein M,Marion MJ,Lehman T,Welsh J,Harris CC,Martel-Planche G,Kusters I,Montesano R.p53mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers.Carcinogenesis1994;15:1-3[PMID:8293534 DOI:10.1093/carcin/15.1.1]
43 Przygodzki RM,Finkelstein SD,Keohavong P,Zhu D,Bakker A,Swalsky PA,Soini Y,Ishak KG,Bennett WP.Sporadic and Thorotrast-induced angiosarcomas of the liver manifest frequent and multiple point mutations in K-ras-2.Lab Invest 1997;76:153-159[PMID:9010458 DOI:10.1121/1.417965]
44 Zhu YP,Chen YM,Matro E,Chen RB,Jiang ZN,Mou YP,Hu HJ,Huang CJ,Wang GY.Primary hepatic angiosarcoma:A report of two cases and literature review.World J Gastroenterol 2015;21:6088-6096[PMID:26019478 DOI:10.3748/wjg.v21.i19.6088]
45 Leowardi C,Hormann Y,Hinz U,Wente MN,Hallscheidt P,Flechtenmacher C,Buchler MW,Friess H,Schwarzbach MH.Ruptured angiosarcoma of the liver treated by emergency catheter-directed embolization.World J Gastroenterol 2006;12:804-808[PMID:16521200 DOI:10.3748/wjg.v12.i5.804]
46 Alves VAF,Rimola J.Malignant Vascular Tumors of the Liver in Adults.Semin Liver Dis 2019;39:1-12[PMID:30536289 DOI:10.1055/s-0038-1676120]
47 Wong JW,Bedard YC.Fine-needle aspiration biopsy of hepatic angiosarcoma:report of a case with immunocytochemical findings.Diagn Cytopathol 1992;8:380-383[PMID:1638939 DOI:10.1002/dc.2840080416]
48 Wang L,Lv K,Chang XY,Xia Y,Yang ZY,Jiang YX,Dai Q,Tan L,Li JC.Contrast-enhanced ultrasound study of primary hepatic angiosarcoma:a pitfall of non-enhancement.Eur J Radiol 2012;81:2054-2059[PMID:21737220 DOI:10.1016/j.ejrad.2011.06.026]
49 Park YS,Kim JH,Kim KW,Lee IS,Yoon HK,Ko GY,Sung KB.Primary hepatic angiosarcoma:imaging findings and palliative treatment with transcatheter arterial chemoembolization or embolization.Clin Radiol 2009;64:779-785[PMID:19589416 DOI:10.1016/j.crad.2009.02.019]
50 Kamatani T,Iguchi H,Okada T,Yamazaki H,Tsunoda H,Watanabe M,Oda M,Ohbu M,Yokomori H.Co-registered positron emission tomography/computed tomography and gadolinium-ethoxybenzyldiethylenetriamine pentaacetic acid magnetic resonance imaging features of multiple angiosarcoma of the liver.Hepatol Res 2014;44:E297-E303[PMID:24147907 DOI:10.1111/hepr.12261]
51 Bruegel M,Muenzel D,Waldt S,Specht K,Rummeny EJ.Hepatic angiosarcoma:cross-sectional imaging findings in seven patients with emphasis on dynamic contrast-enhanced and diffusion-weighted MRI.Abdom Imaging 2013;38:745-754[PMID:23223833 DOI:10.1007/s00261-012-9967-2]
52 Maeda T,Tateishi U,Hasegawa T,Ojima H,Arai Y,Sugimura K.Primary hepatic angiosarcoma on coregistered FDG PET and CT images.AJR Am J Roentgenol 2007;188:1615-1617[PMID:17515384DOI:10.2214/AJR.05.0830]
53 Li DB,Si XY,Wan T,Zhou YM.A pooled analysis of treatment and prognosis of hepatic angiosarcoma in adults.Hepatobiliary Pancreat Dis Int 2018;17:198-203[PMID:29724676 DOI:10.1016/j.hbpd.2018.04.005]
54 Lin YH,Lin CC,Concejero AM,Yong CC,Kuo FY,Wang CC.Surgical experience of adult primary hepatic sarcomas.World J Surg Oncol 2015;13:87[PMID:25880743 DOI:10.1186/s12957-015-0489-6]
55 Orlando G,Adam R,Mirza D,Soderdahl G,Porte RJ,Paul A,Burroughs AK,Seiler CA,Colledan M,Graziadei I,Garcia Valdecasas JC,Pruvot FR,Karam V,Lerut J.Hepatic hemangiosarcoma:an absolute contraindication to liver transplantation--the European Liver Transplant Registry experience.Transplantation 2013;95:872-877[PMID:23354302 DOI:10.1097/TP.0b013e318281b902]
56 Husted TL,Neff G,Thomas MJ,Gross TG,Woodle ES,Buell JF.Liver transplantation for primary or metastatic sarcoma to the liver.Am J Transplant 2006;6:392-397[PMID:16426326 DOI:10.1111/j.1600-6143.2005.01179.x]
57 Huang NC,Kuo YC,Chiang JC,Hung SY,Wang HM,Hung YM,Chang YT,Wann SR,Chang HT,Wang JS,Ho SY,Guo HR.Hepatic angiosarcoma may have fair survival nowadays.Medicine(Baltimore)2015;94:e816[PMID:25984668 DOI:10.1097/MD.0000000000000816]
58 Kim HR,Rha SY,Cheon SH,Roh JK,Park YN,Yoo NC.Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma.Ann Oncol 2009;20:780-787[PMID:19179547 DOI:10.1093/annonc/mdn702]
59 Asmane I,Litique V,Heymann S,Marcellin L,Métivier AC,Duclos B,Bergerat JP,Kurtz JE.Adriamycin,cisplatin,ifosfamide and paclitaxel combination as front-line chemotherapy for locally advanced and metastatic angiosarcoma.Analysis of three case reports and review of the literature.Anticancer Res 2008;28:3041-3045[PMID:19031953 DOI:10.1097/CAD.0b013e32830c2380]
60 Pierce DB,Johnson GE,Monroe E,Loggers ET,Jones RL,Pollack SM,Padia SA.Safety and Efficacy Outcomes of Embolization in Hepatic Sarcomas.AJR Am J Roentgenol 2018;210:175-182[PMID:29090997 DOI:10.2214/AJR.16.17573]
61 Young RJ,Woll PJ.Anti-angiogenic therapies for the treatment of angiosarcoma:a clinical update.Memo2017;10:190-193[PMID:29250195 DOI:10.1007/s12254-017-0365-x]
62 Mitsui F,Aikata H,Hashimoto Y,Nagaoki Y,Kimura Y,Katamura Y,Kawaoka T,Takaki S,Hiraga N,Tsuge M,Waki K,Hiramatsu A,Imamura M,Kawakami Y,Takahashi S,Arihiro K,Chayama K.A first case of hepatic angiosarcoma treated with recombinant interleukin-2.Hiroshima J Med Sci 2011;60:91-96[PMID:22389954 DOI:10.5980/jpnjurol.103.697]
63 Sindhu S,Gimber LH,Cranmer L,McBride A,Kraft AS.Angiosarcoma treated successfully with antiPD-1 therapy-a case report.J Immunother Cancer 2017;5:58[PMID:28716069 DOI:10.1186/s40425-017-0263-0]
64 Pandiaraja J,Subramanian V.A Case of Primary Hemangiopericytoma of Liver.J Med Sci 2015;35:169-172[DOI:10.4103/1011-4564.163825]
65 Guillou L,Fletcher JA,Fletcher CD,Mandahl N,Fletcher CDM,Unni KK,Mertens F.Extrapleural solitary fibrous tumor and hemangiopericytoma.Fletcher CDM,Unni KK,Mertens F.WHO classification of tumours:Pathology and genetics of tumours of soft tissue and bone.Lyon:IARC Press 2002;86-90
66 Lehmann C,Mourra N,Tubiana JM,ArrivéL.[Solitary fibrous tumor of the liver].J Radiol 2006;87:139-142[PMID:16484938 DOI:10.1016/S0221-0363(06)73986-5]
67 Liang YM,Li XH,LüYL,Zhong M.[Morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors].Zhonghua Yi Xue Za Zhi 2005;85:96-100[PMID:15774214 DOI:10.3760/j:issn:0376-2491.2005.02.007]
68 Zimmermann A.Solitary fibrous tumor/hemangiopericytoma of the liver.In:Tumors and tumor-like lesions of the hepatobiliary tract.Springer,Cham 2017;1057-1067[DOI:10.1007/978-3-319-26956-6_61]
69 Caruso S,Gruttadauria S,Minervini MI,Miraglia R,Milazzo M,Luca A,Gridelli B.Primary hemangiopericytoma of the liver:sonographic findings.J Clin Ultrasound 2009;37:305-307[PMID:19253347 DOI:10.1002/jcu.20567]
70 Adams J,Lodge JP,Parker D.Liver transplantation for metastatic hemangiopericytoma associated with hypoglycemia.Transplantation 1999;67:488-489[PMID:10030302 DOI:10.1097/00007890-199902150-00027]
71 Flores-Stadler EM,Chou P,Walterhouse D,Bourtsos E,Gonzalez-Crussi F.Hemangiopericytoma of the liver:immunohistochemical observations,expression of angiogenic factors,and review of the literature.JPediatr Hematol Oncol 1997;19:449-454[PMID:9329468 DOI:10.1097/00043426-199709000-00008]
72 Uemura S,Kuratsu J,Hamada J,Yoshioka S,Kochi M,Ushio Y,Nakahara T,Kishida K.Effect of radiation therapy against intracranial hemangiopericytoma.Neurol Med Chir(Tokyo)1992;32:328-332[PMID:1381057 DOI:10.2176/nmc.32.328]
73 Beadle GF,Hillcoat BL.Treatment of advanced malignant hemangiopericytoma with combination adriamycin and DTIC:a report of four cases.J Surg Oncol 1983;22:167-170[PMID:6682161 DOI:10.1002/jso.2930220306]
74 Galanis E,Buckner JC,Scheithauer BW,Kimmel DW,Schomberg PJ,Piepgras DG.Management of recurrent meningeal hemangiopericytoma.Cancer 1998;82:1915-1920[PMID:9587125 DOI:10.1002/(SICI)1097-0142(19980515)82:103.0.CO;2-W]
75 Chamberlain MC,Glantz MJ.Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma.Neurosurgery 2008;63:720-6;author reply 726-7[PMID:18981882 DOI:10.1227/01.NEU.0000325494.69836.51]
76 Constantinidou A,Jones RL,Scurr M,Al-Muderis O,Judson I.Systemic therapy in solitary fibrous tumour[abstract#39407].15th Connective Tissue Oncologic Society Annual Meeting,Miami,FL.2009
77 Park MS,Patel SR,Ludwig JA,Trent JC,Conrad CA,Lazar AJ,Wang WL,Boonsirikamchai P,Choi H,Wang X,Benjamin RS,Araujo DM.Activity of temozolomide and bevacizumab in the treatment of locally advanced,recurrent,and metastatic hemangiopericytoma and malignant solitary fibrous tumor.Cancer 2011;117:4939-4947[PMID:21480200 DOI:10.1002/cncr.26098]
78 Casali PG,Stacchiotti S,Palassini E,Marrari A,Morosi C,Messina A.Evaluation of the antitumor activity of sunitinib malate(SM)in solitary fibrous tumor(SFT).J Clin Oncol 2009;27(15S);abstr 10571
79 Maki RG,D'Adamo DR,Keohan ML,Saulle M,Schuetze SM,Undevia SD,Livingston MB,Cooney MM,Hensley ML,Mita MM,Takimoto CH,Kraft AS,Elias AD,Brockstein B,Blachère NE,Edgar MA,Schwartz LH,Qin LX,Antonescu CR,Schwartz GK.Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.J Clin Oncol 2009;27:3133-3140[PMID:19451436 DOI:10.1200/JCO.2008.20.4495]
80 Bonetti F,Pea M,Martignoni G,Zamboni G.PEC and sugar.Am J Surg Pathol 1992;16:307-308[PMID:1599021 DOI:10.1097/00000478-199203000-00013]
81 Folpe AL,Kwiatkowski DJ.Perivascular epithelioid cell neoplasms:pathology and pathogenesis.Hum Pathol 2010;41:1-15[PMID:19604538 DOI:10.1016/j.humpath.2009.05.011]
82 Parfitt JR,Bella AJ,Izawa JI,Wehrli BM.Malignant neoplasm of perivascular epithelioid cells of the liver.Arch Pathol Lab Med 2006;130:1219-1222[PMID:16879028 DOI:10.1043/1543-2165(2006)130[1219:MNOPEC]2.0.CO;2]
83 Bonetti F,Martignoni G,Colato C,Manfrin E,Gambacorta M,Faleri M,Bacchi C,Sin VC,Wong NL,Coady M,Chan JK.Abdominopelvic sarcoma of perivascular epithelioid cells.Report of four cases in young women,one with tuberous sclerosis.Mod Pathol 2001;14:563-568[PMID:11406657 DOI:10.1038/modpathol.3880351]
84 Zhao LJ,Yang YJ,Wu H,Huang SM,Liu K.Perivascular epithelioid cell tumor of the liver:a case report and literature review.Eur Rev Med Pharmacol Sci 2013;17:1665-1668[PMID:23832736 DOI:10.1345/aph.1R620]
85 Harris GC,McCulloch TA,Perks G,Fisher C.Malignant perivascular epithelioid cell tumour("PEComa")of soft tissue:a unique case.Am J Surg Pathol 2004;28:1655-1658[PMID:15577688 DOI:10.1097/00000478-200412000-00017]
86 Lehman NL.Malignant PEComa of the skull base.Am J Surg Pathol 2004;28:1230-1232[PMID:15316324 DOI:10.1097/01.pas.0000128668.34934.81]
87 Sadeghi S,Krigman H,Maluf H.Perivascular epithelioid clear cell tumor of the common bile duct.Am JSurg Pathol 2004;28:1107-1110[PMID:15252321 DOI:10.1097/01.pas.0000116831.81882.d0]
88 Silva EG,Deavers MT,Bodurka DC,Malpica A.Uterine epithelioid leiomyosarcomas with clear cells:reactivity with HMB-45 and the concept of PEComa.Am J Surg Pathol 2004;28:244-249[PMID:15043315 DOI:10.1097/00000478-200402000-00013]
89 Tsui WM,Colombari R,Portmann BC,Bonetti F,Thung SN,Ferrell LD,Nakanuma Y,Snover DC,Bioulac-Sage P,Dhillon AP.Hepatic angiomyolipoma:a clinicopathologic study of 30 cases and delineation of unusual morphologic variants.Am J Surg Pathol 1999;23:34-48[PMID:9888702 DOI:10.1097/00000478-199901000-00004]
90 Martignoni G,Pea M,Reghellin D,Zamboni G,Bonetti F.PEComas:the past,the present and the future.Virchows Arch 2008;452:119-132[PMID:18080139 DOI:10.1007/s00428-007-0509-1]
91 Pan CC,Chung MY,Ng KF,Liu CY,Wang JS,Chai CY,Huang SH,Chen PC,Ho DM.Constant allelic alteration on chromosome 16p(TSC2 gene)in perivascular epithelioid cell tumour(PEComa):genetic evidence for the relationship of PEComa with angiomyolipoma.J Pathol 2008;214:387-393[PMID:18085521 DOI:10.1002/path.2289]
92 Zhang X,Wang L,Jiang Y,Wan Z,Li W,Yao C,Geng Z,Lv Y.Hepatic perivascular epithelioid cell tumors-not otherwise specified:a case report.Nan Fang Yi Ke Da Xue Xue Bao 2014;34:1-4[PMID:24463106]
93 Folpe AL,Mentzel T,Lehr HA,Fisher C,Balzer BL,Weiss SW.Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin:a clinicopathologic study of 26 cases and review of the literature.Am J Surg Pathol 2005;29:1558-1575[PMID:16327428 DOI:10.1097/01.pas.0000173232.22117.37]
94 Petrolla AA,Xin W.Hepatic angiomyolipoma.Arch Pathol Lab Med 2008;132:1679-1682[PMID:18834230 DOI:10.1043/1543-2165(2008)132[1679:HA]2.0.CO;2]
95 Fadare O,Parkash V,Yilmaz Y,Mariappan MR,Ma L,Hileeto D,Qumsiyeh MB,Hui P.Perivascular epithelioid cell tumor(PEComa)of the uterine cervix associated with intraabdominal"PEComatosis":Aclinicopathological study with comparative genomic hybridization analysis.World J Surg Oncol 2004;2:35[PMID:15494070 DOI:10.1186/1477-7819-2-35]
96 Zavala-Pompa A,Folpe AL,Jimenez RE,Lim SD,Cohen C,Eble JN,Amin MB.Immunohistochemical study of microphthalmia transcription factor and tyrosinase in angiomyolipoma of the kidney,renal cell carcinoma,and renal and retroperitoneal sarcomas:comparative evaluation with traditional diagnostic markers.Am J Surg Pathol 2001;25:65-70[PMID:11145253 DOI:10.1097/00000478-200101000-00007]
97 Priola AM,Priola SM,Cataldi A,Marci V,Fava C.Acute abdomen as an unusual presentation of hepatic PEComa.A case report.Tumori 2009;95:123-128[PMID:19366072 DOI:10.1177/030089160909500124]
98 Son HJ,Kang DW,Kim JH,Han HY,Lee MK.Hepatic perivascular epithelioid cell tumor(PEComa):a case report with a review of literatures.Clin Mol Hepatol 2017;23:80-86[PMID:28288506 DOI:10.3350/cmh.2016.0034]
99 Stone CH,Lee MW,Amin MB,Yaziji H,Gown AM,Ro JY,Têtu B,Paraf F,Zarbo RJ.Renal angiomyolipoma:further immunophenotypic characterization of an expanding morphologic spectrum.Arch Pathol Lab Med 2001;125:751-758[PMID:11371226 DOI:10.1016/j.susc.2006.09.001]
100 Tan Y,Zhang H,Xiao EH.Perivascular epithelioid cell tumour:dynamic CT,MRI and clinicopathological characteristics--analysis of 32 cases and review of the literature.Clin Radiol 2013;68:555-561[PMID:23245276 DOI:10.1016/j.crad.2012.10.021]
101 Maebayashi T,Abe K,Aizawa T,Sakaguchi M,Ishibashi N,Abe O,Takayama T,Nakayama H,Matsuoka S,Nirei K,Nakamura H,Ogawa M,Sugitani M.Improving recognition of hepatic perivascular epithelioid cell tumor:Case report and literature review.World J Gastroenterol 2015;21:5432-5441[PMID:25954119 DOI:10.3748/wjg.v21.i17.5432]
102 Tirumani SH,Shinagare AB,Hargreaves J,Jagannathan JP,Hornick JL,Wagner AJ,Ramaiya NH.Imaging features of primary and metastatic malignant perivascular epithelioid cell tumors.AJR Am JRoentgenol 2014;202:252-258[PMID:24450662 DOI:10.2214/AJR.13.10909]
103 Kumasaka S,Arisaka Y,Tokue A,Higuchi T,Nakajima T,Tsushima Y.A case of multiple hepatic angiomyolipomas with high(18)?F-fluorodeoxyglucose uptake.BMC Med Imaging 2014;14:17[PMID:24885757 DOI:10.1186/1471-2342-14-17]
104 Deng YF,Lin Q,Zhang SH,Ling YM,He JK,Chen XF.Malignant angiomyolipoma in the liver:a case report with pathological and molecular analysis.Pathol Res Pract 2008;204:911-918[PMID:18723294DOI:10.1016/j.prp.2008.06.007]
105 Khaja F,Carilli A,Baidas S,Sriharan A,Norford S.PEComa:A Perivascular Epithelioid Cell Tumor in the Liver-A Case Report and Review of the Literature.Case Rep Med 2013;2013:904126[PMID:24489554 DOI:10.1155/2013/904126]
106 Kirste S,Kayser G,Zipfel A,Grosu AL,Brunner T.Unresectable hepatic PEComa:a rare malignancy treated with stereotactic body radiation therapy(SBRT)followed by complete resection.Radiat Oncol2018;13:28[PMID:29463266 DOI:10.1186/s13014-018-0974-5]
107 Guan H,Zou Y,Lv Y,Wang C.Hepatic perivascular epithelioid cell tumor treated by transarterial embolization plus radiofrequency ablation:A case report and literature review.Medicine(Baltimore)2017;96:e6969[PMID:28562547 DOI:10.1097/MD.0000000000006969]
108 Bergamo F,Maruzzo M,Basso U,Montesco MC,Zagonel V,Gringeri E,Cillo U.Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor(PEComa).World J Surg Oncol 2014;12:46[PMID:24575738 DOI:10.1186/1477-7819-12-46]
109 Bleeker JS,Quevedo JF,Folpe AL."Malignant"perivascular epithelioid cell neoplasm:risk stratification and treatment strategies.Sarcoma 2012;2012:541626[PMID:22619565 DOI:10.1155/2012/541626]
110 Wagner AJ,Malinowska-Kolodziej I,Morgan JA,Qin W,Fletcher CD,Vena N,Ligon AH,Antonescu CR,Ramaiya NH,Demetri GD,Kwiatkowski DJ,Maki RG.Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors:targeting the pathogenic activation of mTORC1 in tumors.J Clin Oncol 2010;28:835-840[PMID:20048174 DOI:10.1200/JCO.2009.25.2981]
111 Tacconi D,Vergori A,Lapini L,Magnolfi A,Carnevali A,Caremani M.Hepatic Kaposi's sarcoma in a patient affected by AIDS:Correlation between histology and imaging.J Ultrasound 2012;15:215-219[PMID:23730384 DOI:10.1016/j.jus.2012.10.004]
112 Giuliani M,Cordiali-Fei P,Castilletti C,Di Carlo A,Palamara G,Boros S,Rezza G.Incidence of human herpesvirus 8(HHV-8)infection among HIV-uninfected individuals at high risk for sexually transmitted infections.BMC Infect Dis 2007;7:143[PMID:18053246 DOI:10.1186/1471-2334-7-143]
113 Lodi S,Guiguet M,Costagliola D,Fisher M,de Luca A,Porter K;CASCADE Collaboration.Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion.J Natl Cancer Inst 2010;102:784-792[PMID:20442214 DOI:10.1093/jnci/djq134]
114 Bhutani M,Polizzotto MN,Uldrick TS,Yarchoan R.Kaposi sarcoma-associated herpesvirus-associated malignancies:epidemiology,pathogenesis,and advances in treatment.Semin Oncol 2015;42:223-246[PMID:25843728 DOI:10.1053/j.seminoncol.2014.12.027]
115 Shiels MS,Pfeiffer RM,Gail MH,Hall HI,Li J,Chaturvedi AK,Bhatia K,Uldrick TS,Yarchoan R,Goedert JJ,Engels EA.Cancer burden in the HIV-infected population in the United States.J Natl Cancer Inst 2011;103:753-762[PMID:21483021 DOI:10.1093/jnci/djr076]
116 Antman K,Chang Y.Kaposi's sarcoma.N Engl J Med 2000;342:1027-1038[PMID:10749966 DOI:10.1056/NEJM200004063421407]
117 Russo JJ,Bohenzky RA,Chien MC,Chen J,Yan M,Maddalena D,Parry JP,Peruzzi D,Edelman IS,Chang Y,Moore PS.Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus(HHV8).Proc Natl Acad Sci USA 1996;93:14862-14867[PMID:8962146 DOI:10.1073/pnas.93.25.14862]
118 Mercader M,Taddeo B,Panella JR,Chandran B,Nickoloff BJ,Foreman KE.Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells.Am J Pathol 2000;156:1961-1971[PMID:10854219 DOI:10.1016/S0002-9440(10)65069-9]
119 Friborg J,Kong W,Hottiger MO,Nabel GJ.p53 inhibition by the LANA protein of KSHV protects against cell death.Nature 1999;402:889-894[PMID:10622254 DOI:10.1038/47266]
120 Nakamura T,Mizuno S.The discovery of hepatocyte growth factor(HGF)and its significance for cell biology,life sciences and clinical medicine.Proc Jpn Acad Ser B Phys Biol Sci 2010;86:588-610[PMID:20551596 DOI:10.2183/pjab.86.588]
121 Hong YK,Foreman K,Shin JW,Hirakawa S,Curry CL,Sage DR,Libermann T,Dezube BJ,Fingeroth JD,Detmar M.Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus.Nat Genet 2004;36:683-685[PMID:15220917 DOI:10.1038/ng1383]
122 Hammock L,Reisenauer A,Wang W,Cohen C,Birdsong G,Folpe AL.Latency-associated nuclear antigen expression and human herpesvirus-8 polymerase chain reaction in the evaluation of Kaposi sarcoma and other vascular tumors in HIV-positive patients.Mod Pathol 2005;18:463-468[PMID:15578080 DOI:10.1038/modpathol.3800221]
123 Schneiderman DJ,Arenson DM,Cello JP,Margaretten W,Weber TE.Hepatic disease in patients with the acquired immune deficiency syndrome(AIDS).Hepatology 1987;7:925-930[PMID:2820858 DOI:10.1002/hep.1840070522]
124 Read PJ,Lucas S,Morris S,Kulasegaram R.Immune reconstitution inflammatory syndrome Kaposi sarcoma in the liver manifesting as acute obstructive hepatitis:another potential role for montelukast?Int JSTD AIDS 2013;24:156-158[PMID:24400347 DOI:10.1177/0956462412472819]
125 Hammerman AM,Kotner LM,Doyle TB.Periportal contrast enhancement on CT scans of the liver.AJRAm J Roentgenol 1991;156:313-315[PMID:1898805 DOI:10.2214/ajr.156.2.1898805]
126 Valls C,Ca?as C,Turell LG,Pruna X.Hepatosplenic AIDS-related Kaposi's sarcoma.Gastrointest Radiol1991;16:342-344[PMID:1936779 DOI:10.1007/BF01887385]
127 Nasti G,Talamini R,Antinori A,Martellotta F,Jacchetti G,Chiodo F,Ballardini G,Stoppini L,Di Perri G,Mena M,Tavio M,Vaccher E,D'Arminio Monforte A,Tirelli U;AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive from Antiretrovirals.AIDS-related Kaposi's Sarcoma:evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals.J Clin Oncol 2003;21:2876-2882[PMID:12885804 DOI:10.1200/JCO.2003.10.162]
128 Maskew M,Fox MP,van Cutsem G,Chu K,Macphail P,Boulle A,Egger M,Africa FI.Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma:a cohort study.PLoS One 2013;8:e64392[PMID:23755122 DOI:10.1371/journal.pone.0064392]
129 Donato V,Guarnaccia R,Dognini J,de Pascalis G,Caruso C,Bellagamba R,Morrone A.Radiation therapy in the treatment of HIV-related Kaposi's sarcoma.Anticancer Res 2013;33:2153-2157[PMID:23645769]
130 Gbabe OF,Okwundu CI,Dedicoat M,Freeman EE.Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.Cochrane Database Syst Rev 2014;CD003256[PMID:25221796 DOI:10.1002/14651858.CD003256.pub2]
131 Van Leer-Greenberg B,Kole A,Chawla S.Hepatic Kaposi sarcoma:A case report and review of the literature.World J Hepatol 2017;9:171-179[PMID:28217255 DOI:10.4254/wjh.v9.i4.171]
132 Stewart S,Jablonowski H,Goebel FD,Arasteh K,Spittle M,Rios A,Aboulafia D,Galleshaw J,Dezube BJ.Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma.International Pegylated Liposomal Doxorubicin Study Group.J Clin Oncol 1998;16:683-691[PMID:9469358 DOI:10.1200/JCO.1998.16.2.683]
133 Grünaug M,Bogner JR,Loch O,Goebel FD.Liposomal doxorubicin in pulmonary Kaposi's sarcoma:improved survival as compared to patients without liposomal doxorubicin.Eur J Med Res 1998;3:13-19[PMID:9512962]
134 Gill PS,Wernz J,Scadden DT,Cohen P,Mukwaya GM,von Roenn JH,Jacobs M,Kempin S,Silverberg I,Gonzales G,Rarick MU,Myers AM,Shepherd F,Sawka C,Pike MC,Ross ME.Randomized phase IIItrial of liposomal daunorubicin versus doxorubicin,bleomycin,and vincristine in AIDS-related Kaposi's sarcoma.J Clin Oncol 1996;14:2353-2364[PMID:8708728 DOI:10.1200/JCO.1996.14.8.2353]
135 Martellotta F,Berretta M,Vaccher E,Schioppa O,Zanet E,Tirelli U.AIDS-related Kaposi's sarcoma:state of the art and therapeutic strategies.Curr HIV Res 2009;7:634-638[PMID:19929800 DOI:10.2174/157016209789973619]
136 Gantt S,Casper C.Human herpesvirus 8-associated neoplasms:the roles of viral replication and antiviral treatment.Curr Opin Infect Dis 2011;24:295-301[PMID:21666458 DOI:10.1097/QCO.0b013e3283486d04]
137 La Ferla L,Pinzone MR,Nunnari G,Martellotta F,Lleshi A,Tirelli U,De Paoli P,Berretta M,Cacopardo B.Kaposi's sarcoma in HIV-positive patients:the state of art in the HAART-era.Eur Rev Med Pharmacol Sci 2013;17:2354-2365[PMID:24065230]
138 Gill RM,Buelow B,Mather C,Joseph NM,Alves V,Brunt EM,Liu TC,Makhlouf H,Marginean C,Nalbantoglu I,Sempoux C,Snover DC,Thung SN,Yeh MM,Ferrell LD.Hepatic small vessel neoplasm,a rare infiltrative vascular neoplasm of uncertain malignant potential.Hum Pathol 2016;54:143-151[PMID:27090685 DOI:10.1016/j.humpath.2016.03.018]
139 Behjati S,Tarpey PS,Sheldon H,Martincorena I,Van Loo P,Gundem G,Wedge DC,Ramakrishna M,Cooke SL,Pillay N,Vollan HKM,Papaemmanuil E,Koss H,Bunney TD,Hardy C,Joseph OR,Martin S,Mudie L,Butler A,Teague JW,Patil M,Steers G,Cao Y,Gumbs C,Ingram D,Lazar AJ,Little L,Mahadeshwar H,Protopopov A,Al Sannaa GA,Seth S,Song X,Tang J,Zhang J,Ravi V,Torres KE,Khatri B,Halai D,Roxanis I,Baumhoer D,Tirabosco R,Amary MF,Boshoff C,McDermott U,Katan M,Stratton MR,Futreal PA,Flanagan AM,Harris A,Campbell PJ.Recurrent PTPRB and PLCG1 mutations in angiosarcoma.Nat Genet 2014;46:376-379[PMID:24633157 DOI:10.1038/ng.2921]
140 Antonescu CR,Yoshida A,Guo T,Chang NE,Zhang L,Agaram NP,Qin LX,Brennan MF,Singer S,Maki RG.KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.Cancer Res 2009;69:7175-7179[PMID:19723655 DOI:10.1158/0008-5472.CAN-09-2068]
141 Lewis S,Aljarallah B,Trivedi A,Thung SN.Magnetic resonance imaging of a small vessel hepatic hemangioma in a cirrhotic patient with histopathologic correlation.Clin Imaging 2015;39:702-706[PMID:25748474 DOI:10.1016/j.clinimag.2015.02.007]
142 Joseph NM,Brunt EM,Marginean C,Nalbantoglu I,Snover DC,Thung SN,Yeh MM,Umetsu SE,Ferrell LD,Gill RM.Frequent GNAQ and GNA14 Mutations in Hepatic Small Vessel Neoplasm.Am JSurg Pathol 2018;42:1201-1207[PMID:29975248 DOI:10.1097/PAS.0000000000001110]
143 Walcott-Sapp S,Tang E,Kakar S,Shen J,Hansen P.Resection of the largest reported hepatic small vessel neoplasm.Hum Pathol 2018;78:159-162[PMID:29366622 DOI:10.1016/j.humpath.2018.01.013]